Alvotech Marks Denosumab Milestone

AVT03 Proposed Biosimilar To Prolia/Xgeva Passes PK Study; Further Trials Ongoing

 
• By David Wallace
  
Alvotech’s AVT03 denosumab candidate has passed a PK study

More from Biosimilars

More from Products